scholarly journals Letter: the role of direct-acting anti-virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virus-induced cirrhosis-Authors' reply

2018 ◽  
Vol 47 (8) ◽  
pp. 1231-1232
Author(s):  
F. Mettke ◽  
H. Wedemeyer
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Direct Acting

scholarly journals Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases

2021 ◽  
Author(s):  
R. Tapia-Sosa ◽  
F. Hernández-Cabral ◽  
A. Gabutti ◽  
V.M. Páez-Zayas ◽  
I. García-Juárez
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Review Viruses in cancer cell plasticity: the role of hepatitis C virus in hepatocellular carcinoma

2015 ◽  
Vol 1A ◽  
pp. 62-67
Author(s):  
Urszula Hibner ◽  
Damien Grégoire
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Cancer Cell ◽  
Cell Plasticity

scholarly journals Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3414
Author(s):  
Hye Won Lee ◽  
Dai Hoon Han ◽  
Hye Jung Shin ◽  
Jae Seung Lee ◽  
Seung Up Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Pegylated Interferon ◽  
Direct Acting Antivirals ◽  
Treatment Regimens ◽  
Direct Acting ◽  
Similar Risk ◽  
Carcinoma Risk

By pegylated interferon (PegIFN)-free direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection, a sustained virological response (SVR) rate >95% can be attained with a satisfactory tolerability and shorter treatment duration. However, it remains controversial whether there is any difference in prognosis depending on regimens—PegIFN or DAAs. We compared the probabilities of hepatocellular carcinoma (HCC) development between patients achieving an SVR by PegIFN/ribavirin (PegIFN group, n = 603) and DAAs (DAAs group, n = 479). The DAAs group was significantly older and had a higher proportion of cirrhosis than the PegIFN group. Before adjustment, the DAAs group had a higher HCC incidence than the PegIFN group (p < 0.001). However, by multivariate analyses, the DAAs (vs. PegIFN) group was not associated with HCC risk (adjusted hazard ratio 0.968, 95% confidence interval 0.380–2.468; p = 0.946). Old age, male, higher body mass index, cirrhosis, and lower platelet count were associated with increased HCC risk (all p < 0.05). After propensity score matching (PSM), a similar HCC risk between the two groups was observed (p = 0.372). We also compared HCC incidences according to sofosbuvir (SOF)-based and SOF-free DAAs, showing a similar risk in both groups before adjustment (p = 0.478) and after PSM (p = 0.855). In conclusion, post-SVR HCC risks were comparable according to treatment regimens; PegIFN- vs. DAA-based regimens and SOF-based vs. SOF-free DAA regimens. Further studies with a longer follow-up period are required.

scholarly journals Absence of differences in the recurrence rates of hepatitis C virus‑associated hepatocellular carcinoma between direct‑acting antivirals and interferon‑based treatments: A multicenter study

2021 ◽  
Vol 3 (3) ◽  
Author(s):  
Atsushi Nakazawa ◽  
Shinichi Fujioka ◽  
Kazuo Notsumata ◽  
Toshihide Shima ◽  
Kimihiko Yangita ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Multicenter Study ◽  
Direct Acting Antivirals ◽  
Recurrence Rates ◽  
Direct Acting

scholarly journals Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV)

2018 ◽  
Vol 28 (4) ◽  
pp. e1984 ◽  
Author(s):  
Jason T. Blackard ◽  
Kenneth E. Sherman
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Potential Role ◽  
Hbv Reactivation ◽  
B Virus ◽  
Direct Acting

scholarly journals The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S201-S202
Author(s):  
Minas Economides ◽  
Jeff Hosry ◽  
Georgios Angelidakis ◽  
Ahmed Kaseb ◽  
Harrys Torres
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Direct Acting Antivirals ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document